8-K: Instil Bio Enters $100 Million Open Market Sale Agreement with Jefferies LLC

Instil Bio, Inc. has entered into an agreement with Jefferies LLC to sell up to $100 million of its common stock through an 'at-the-market' offering.

Summary

• Instil Bio, Inc. has entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell up to $100 million of its common stock.
• The shares will be sold from time to time at the company's option through Jefferies LLC, acting as sales agent or principal.
• The sales will be made pursuant to an existing registration statement on Form S-3 and a related prospectus supplement.
• Jefferies LLC will receive a commission of 3.0% of the gross sales price per share sold.
• The company will also reimburse Jefferies LLC for certain expenses and provide indemnification against certain liabilities.
• Instil Bio is not obligated to sell any shares under the agreement, and either party can terminate the agreement with ten trading days' notice.
• The offering will terminate upon the sale of the maximum dollar value of common stock or with ten trading days' notice from either party.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive. It provides Instil Bio with financial flexibility, but also carries the risk of dilution. The market's reaction will depend on how the company utilizes the raised capital and overall market conditions.

Positives

• The agreement provides Instil Bio with flexibility in raising capital.
• The 'at-the-market' offering allows the company to sell shares gradually, potentially minimizing market impact.
• The company is not obligated to sell shares, providing control over the timing and amount of capital raised.

Negatives

• The company will incur expenses related to the offering, including a 3.0% commission to Jefferies LLC.
• The sale of shares may dilute existing shareholders' ownership.
• There is no guarantee that the company will be able to sell all $100 million of shares.

Risks

• Market conditions may affect the company's ability to sell shares at favorable prices.
• The offering could be terminated prematurely if either party provides ten trading days' notice.
• Dilution of existing shareholders' ownership could negatively impact the stock price.

Future Outlook

The company may sell shares of its common stock from time to time, at its option, through Jefferies LLC. The timing and amount of sales will depend on market conditions and the company's capital needs.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital. This type of offering provides flexibility and can be less dilutive than traditional underwritten offerings.

Comparison to Industry Standards

• Many biotech companies, such as Adaptimmune Therapeutics and CRISPR Therapeutics, have utilized at-the-market offerings to raise capital.
• The 3.0% commission is within the typical range for these types of agreements.
• The $100 million offering size is comparable to other recent ATM offerings in the biotech sector.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the company sells a significant number of shares.
• The company's financial position may be strengthened by the additional capital.
• Employees may benefit from the company's increased financial stability.

Next Steps

• Instil Bio may choose to sell shares of its common stock through Jefferies LLC.
• Jefferies LLC will attempt to place the shares based on the company's instructions.
• The company will file reports detailing the number of shares sold and the net proceeds received.

Key Dates

Keywords

Open Market Sale Agreement, Instil Bio, Jefferies LLC, Common Stock, At-the-market offering, Capital Raise, Securities, Offering